Focus on the Controversial Aspects of (64)Cu-ATSM in Tumoral Hypoxia Mapping by PET Imaging - PubMed (original) (raw)
Review
Focus on the Controversial Aspects of (64)Cu-ATSM in Tumoral Hypoxia Mapping by PET Imaging
Mathilde Colombié et al. Front Med (Lausanne). 2015.
Abstract
Mapping tumor hypoxia is a great challenge in positron emission tomography (PET) imaging as the precise functional information of the biological processes is needed for many effective therapeutic strategies. Tumor hypoxia has been widely reported as a poor prognostic indicator and is often associated with tumor aggressiveness, chemo- and radio-resistance. An accurate diagnosis of hypoxia is a challenge and is crucial for providing accurate treatment for patients' survival benefits. This challenge has led to the emergence of new and novel PET tracers for the functional and metabolic characterization of tumor hypoxia non-invasively. Among these tracers, copper semicarbazone compound [64Cu]-diacetyl-bis(N (4)-methylthiosemicarbazone) (=64Cu-ATSM) has been developed as a tracer for hypoxia imaging. This review focuses on 64Cu-ATSM PET imaging and the concept is presented in two sections. The first section describes its in vitro development and pre-clinical testing and particularly its affinity in different cell lines. The second section describes the controversial reports on its specificity for hypoxia imaging. The review concludes that 64Cu-ATSM - more than a hypoxic tracer, exhibits tracer accumulation in tumor, which is linked to the redox potential and reactive oxygen species. The authors concluded that 64Cu-ATSNM is a marker of over-reduced cell state and thus an indirect marker for hypoxia imaging. The affinity of 64Cu-ATSM for over-reduced cells was observed to be a complex phenomenon. And to provide a definitive and convincing mechanism, more in vivo studies are needed to prove the diagnostic utility of 64Cu-ATSM.
Keywords: [64Cu]-ATSM; cancer; hypoxia; positron emission tomography; radiopharmaceutical; reactive oxygen species.
Figures
Figure 1
[64Cu]-diacetyl-bis(_N_4-methylthiosemicarbazone) (_=_64Cu-ATSM).
Figure 2
Overview of the cellular 64Cu-ATSM uptake and retention mechanisms. In hypoxic condition, the Cu(II)-ATSM (oxidation level of copper-64 is +II) is reduced to Cu(I)-ATSM (oxidation level of copper-64 is +I) then the complex became instable and free copper-64 is trapped and accumulate in intracellular copper chaperones proteins.
Figure 3
Overproduction of reductive species (NADPH and NADH) in mitochondria during hypoxia. Under normoxia, NADH produced during the tricarboxylic acid (TCA) cycle are reduced in NAD+ and the respiratory chain drove the electron (dash arrow) to dioxygen with a proton flux on the intermembrane space whose flow back on the mitochondrial matrix by the ATP synthase produced ATP. During hypoxia, the respiratory chain is inhibited and we observe an accumulation of overreduced species (NADH and NADPH) and a diminution (in long-term) of ROS production.
Similar articles
- A limited overlap between intratumoral distribution of 1-(5-fluoro-5-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole and copper-diacetyl-bis[N(4)-methylthiosemicarbazone].
Furukawa T, Yuan Q, Jin ZH, Aung W, Yoshii Y, Hasegawa S, Endo H, Inoue M, Zhang MR, Fujibayashi Y, Saga T. Furukawa T, et al. Oncol Rep. 2015 Sep;34(3):1379-87. doi: 10.3892/or.2015.4079. Epub 2015 Jun 25. Oncol Rep. 2015. PMID: 26134305 - A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy.
Chao KS, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA, Dempsey JF, Perez CA, Purdy JA, Welch MJ. Chao KS, et al. Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1171-82. doi: 10.1016/s0360-3016(00)01433-4. Int J Radiat Oncol Biol Phys. 2001. PMID: 11240261 - Hypoxia imaging and theranostic potential of [64Cu][Cu(ATSM)] and ionic Cu(II) salts: a review of current evidence and discussion of the retention mechanisms.
Liu T, Karlsen M, Karlberg AM, Redalen KR. Liu T, et al. EJNMMI Res. 2020 Apr 9;10(1):33. doi: 10.1186/s13550-020-00621-5. EJNMMI Res. 2020. PMID: 32274601 Free PMC article. Review. - Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).
Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW. Yuan H, et al. J Nucl Med. 2006 Jun;47(6):989-98. J Nucl Med. 2006. PMID: 16741309 - Contribution of [64Cu]-ATSM PET in molecular imaging of tumour hypoxia compared to classical [18F]-MISO--a selected review.
Bourgeois M, Rajerison H, Guerard F, Mougin-Degraef M, Barbet J, Michel N, Cherel M, Faivre-Chauvet A. Bourgeois M, et al. Nucl Med Rev Cent East Eur. 2011;14(2):90-5. doi: 10.5603/nmr.2011.00022. Nucl Med Rev Cent East Eur. 2011. PMID: 22219149 Review.
Cited by
- Monte Carlo Evaluation of Dose Enhancement Due to CuATSM or GNP Uptake in Hypoxic Environments with External Beam Radiation.
Martinez S, Brandl A, Leary D. Martinez S, et al. Int J Nanomedicine. 2020 May 27;15:3719-3727. doi: 10.2147/IJN.S241756. eCollection 2020. Int J Nanomedicine. 2020. PMID: 32547024 Free PMC article. - 64Cu-based Radiopharmaceuticals in Molecular Imaging.
Zhou Y, Li J, Xu X, Zhao M, Zhang B, Deng S, Wu Y. Zhou Y, et al. Technol Cancer Res Treat. 2019 Jan 1;18:1533033819830758. doi: 10.1177/1533033819830758. Technol Cancer Res Treat. 2019. PMID: 30764737 Free PMC article. Review. - 64Cu-ATSM Predicts Efficacy of Carbon Ion Radiotherapy Associated with Cellular Antioxidant Capacity.
Nachankar A, Oike T, Hanaoka H, Kanai A, Sato H, Yoshida Y, Obinata H, Sakai M, Osu N, Hirota Y, Takahashi A, Shibata A, Ohno T. Nachankar A, et al. Cancers (Basel). 2021 Dec 7;13(24):6159. doi: 10.3390/cancers13246159. Cancers (Basel). 2021. PMID: 34944777 Free PMC article. - Cellular Uptake of the ATSM-Cu(II) Complex under Hypoxic Conditions.
Walke GR, Meron S, Shenberger Y, Gevorkyan-Airapetov L, Ruthstein S. Walke GR, et al. ChemistryOpen. 2021 Apr;10(4):486-492. doi: 10.1002/open.202100044. ChemistryOpen. 2021. PMID: 33908707 Free PMC article. - A Review of Nuclear Medicine Approaches in the Diagnosis and the Treatment of Gynecological Malignancies.
Vahidfar N, Farzanefar S, Ahmadzadehfar H, Molloy EN, Eppard E. Vahidfar N, et al. Cancers (Basel). 2022 Mar 31;14(7):1779. doi: 10.3390/cancers14071779. Cancers (Basel). 2022. PMID: 35406552 Free PMC article. Review.
References
- Chapman JD, Baer K, Lee J. Characteristics of the metabolism-induced binding of misonidazole to hypoxic mammalian cells. Cancer Res (1983) 43:1523–8. - PubMed
- Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med (1997) 38:1155–60. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous